Description
China’s Roxatidine Market
Peptic ulcers and gastrointestinal bleeding are common diseases in China with a large number of patients. Due to the fast pace of modern life, accelerated urbanization and great mental stress, the number of cases is increasing year by year, and the incidence of digestive diseases accounts for 10%-20% of the total Chinese population with extremely high recurrence rate.
There is no significant difference between H2RA and PPIs in the incidence of risk events related to increased gastric acidity and gastrointestinal bleeding, and they can both greatly reduce the costs associated with stress ulcer prophylaxis. Therefore, industry insiders believe that H2RA may be more cost-effective.
Roxatidine is a long-acting H2RA with a stronger-than-ranitidine acid-suppressive effect and a mucosal protective effect. The effective dose of roxatidine is 150 mg/day, which is three to six times more effective than cimetidine and twice as effective as ranitidine. Clinical data show that in the comparison of H2 receptor antagonists for peptic ulcer recurrence rate, the rate is the smallest when using roxatidine.
Roxatidine is a fourth generation H2 receptor blocker and is available in oral and injectable dosage forms.
Roxatidine, originally developed by ASKA Pharmaceutical Co., Ltd, was first marketed in Japan in 1986 in the oral form for the treatment of gastric and duodenal ulcers, Zollinger-Ellison syndrome, reflux esophagitis and gastritis; the injectable form, first marketed in Japan in 1995 for the treatment of upper gastrointestinal bleeding and pre-anesthesia, was one of the few drugs used for peptic ulcers and bleeding in hospitalized patients.
According to CRI’s market research, the roxatidine from the original developer, ASKA Pharmaceutical is not marketed in China. As of August 2021, only two companies, Beijing Sihuan Pharmaceutical and HPGC Bioengineering have obtained the approval for manufacturing roxatidine in the Chinese market, with Beijing Sihuan Pharmaceutical occupies the most market share.
Up till now, the only dosage form of roxatidine available in the Chinese market is injection, and it is expected that oral preparations may be available in the next few years.
According to CRI’s market research, the market size of roxatidine in China kept growing from 2016 to 2020. In 2020, despite the impact of COVID-19, the sales value of roxatidine in the Chinese market increased to CNY428 million (approximately USD65.8 million), with a CAGR of 37.3% from 2016 to 2020.
CRI expects that from 2021 to 2025, the market size of roxatidine in China will continue to grow as the number of patients with digestive diseases in China keep increasing, and the average sales price of roxatidine in China will decrease due to the competitive market while both sales volume and value will continue to rise.
Topics Covered:
- Impact of COVID-19 on China’s Roxatidine Market
- Development Environment of Roxatidine in China
- Sales Volume of Roxatidine in China
- Sales Volume and Value of Roxatidine in China by Region
- Major Roxatidine Manufacturers in China and Their Market Shares
- Sales Price of Roxatidine in China
- Prospects of China’s Roxatidine Market, 2021-2025
